Licart System
Product Images NDC 72989-458

4 FDA label images from Acertis Pharmaceuticals Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Licart (NDC 72989-458). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Acertis Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Chemical Structure (Licart 01)

Chemical Structure (Licart 01)
Chemical structure diagram showing the active ingredient diclofenac epolamine, with detailed molecular structures for diclofenac and epolamine components.*
FDA Label Image

Figure 1 (Licart 02)

Figure 1 (Licart 02)
A line graph showing mean pain levels on a scale from 0 to 100 over a 16-day treatment period, comparing LICART (diclofenac epolamine) and placebo. The graph indicates a decrease in pain levels over time for both groups, with the LICART group consistently showing lower mean pain levels than the placebo group throughout the treatment days.*
FDA Label Image

Figure 2 (Licart 03)

Figure 2 (Licart 03)
A line chart labeled Protocol 06EU/FHp03 showing mean pain levels on a scale from 0 to 100 by treatment day for LICART and placebo groups. The x-axis represents treatment days 1 to 8, and the y-axis shows mean pain levels. Both groups show decreasing pain over time, with LICART consistently having lower pain levels than placebo throughout the treatment period.*
FDA Label Image

15 Pack (Acertis Licart 15)

15 Pack (Acertis Licart 15)
Packaging label for LICART diclofenac epolamine topical system 1.3%, a human prescription drug in systemic topical form. The label shows a 15 count package of 10 cm x 14 cm topical systems, manufactured by Acertis Pharmaceuticals LLC. Directions for application and warnings are displayed, along with a reminder to change LICART once daily every 24 hours. The label highlights dosage strength and includes the NDC 72989-458-55.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.